Lorlatinib as Neoadjuvant Treatment in Stage IB-IIIB ALK-rearranged Non-Small Cell Lung Cancer
Clinical trial NCT06682884 · NOT_YET_RECRUITING
Trial details
- NCT number
- NCT06682884
- Sponsor
- Peking University People's Hospital
- Status
- NOT_YET_RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2024-11-15
- Primary completion
- 2026-04-30
- Enrollment
- 25
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.